Clinical trial
Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus…
NCT00005017 · Glaxo Wellcome, Industry · Unknown status
Key facts
| NCT number | NCT00005017 |
|---|---|
| Title | Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment |
| Official title | A Phase IV, Open-Label, Randomized Study to Compare the Efficacy and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) for 96 Weeks in the Treatment of HIV-1 Infected Subjects Who Are Antiretroviral Therapy… |
| Lead sponsor | Glaxo Wellcome, Industry |
| Status | Unknown status |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Ritonavir, Abacavir sulfate, Amprenavir, Efavirenz, Lamivudine, Stavudine |
| Enrollment | 300 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: